ArticleJournal of gastroenterology2014
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Article in Journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Review
- Article
- Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Article
- Article
- Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.European radiology · 2018Article
- Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2018Article
- Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.Liver cancer · 2018Article
- Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.Hepatic oncology · 2017Review
- Non-coding RNAs, the Trojan horse in two-way communication between tumor and stroma in colorectal and hepatocellular carcinoma.Oncotarget · 2017Review
- How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma.World journal of hepatology · 2016Review
- Challenges of advanced hepatocellular carcinoma.World journal of gastroenterology · 2016Review
- Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.BMC research notes · 2015Article
- Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up.World journal of hepatology · 2015Review
- Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.International journal of molecular sciences · 2015Article
- The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.BioMed research international · 2015Review
- Observational
- Biomarkers and Personalized Sorafenib Therapy.Liver cancer · 2014Article
- Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved evaluation system designed to address the limitations of the response evaluation criteria in solid tumors 1.1 (RECIST1.1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS).
methodsThe therapeutic response of 156 patients with advanced HCC who had been treated with sorafenib therapy for more than 1 month was evaluated using the RECIST1.1, mRECIST, and RECICL. After categorization as showing progressive disease (PD), stable disease (SD), or objective response, the association between OS and categorization was examined using the Kaplan-Meier method to develop survival curves. The 141 cases categorized as PD or SD by the RECIST1.1, but objective response by the mRECIST and RECICL, were further analyzed for determination of the association between OS and categorization.
resultsOnly categorization using the RECICL was found to be significantly correlated with OS (p = 0.0033). Among the patients categorized as SD or PD by the RECIST1.1, reclassification by the RECICL but not the mRECIST was found to be significantly associated with OS and allowed for precise prediction of prognosis (p = 0.0066).
conclusionsOnly the use of the RECICL allowed for identification of a subgroup of HCC patients treated with sorafenib with improved prognosis. The RECICL should, therefore, be considered a superior system for assessment of therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.